Oncolytic Virus Cancer Therapy Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Therapeutics Segment
Explore our latest breakthroughs in Oncolytic Virus Cancer Therapy Research. Learn more about our innovative pipeline today! @ Oncolytic Virus Cancer Therapy Pipeline Outlook
Key Takeaways from the Oncolytic Virus Cancer Therapy Pipeline Report
In June 2025, Replimune Inc. conducted a study is to evaluate whether treatment with RP2 can provide efficacy as 2L treatment combined with atezolizumab plus bevacizumab in patients with locally advanced unresectable, recurrent, and/or metastatic HCC.
DelveInsight's Oncolytic Virus Cancer Therapy pipeline report depicts a robust space with 120+ active players working to develop 125+ pipeline therapies for Oncolytic Virus Cancer Therapy treatment.
The leading Oncolytic Virus Cancer Therapy Companies such as Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Oncolys BioPharma, Turnstone Biologics and others.
Promising Oncolytic Virus Cancer Therapy Pipeline Therapies such as Gemcitabine, Valacyclovir, CG0070, Keytruda, atezolizumab, Ipilimumab, TBI-1401(HF10), Bevacizumab, Sorafenib, Pembrolizumab, Talimogene Laherparepvec and others.
Stay informed about the cutting-edge advancements in Oncolytic Virus Cancer Therapy treatments. Download for updates and be a part of the revolution in Oncology Care @ Oncolytic Virus Cancer Therapy Clinical Trials Assessment
Oncolytic Virus Cancer Therapy Emerging Drugs Profile
Olvi-Vec: Genelux Corporation
Olvi-Vec is a proprietary, non-pathogenic oncolytic vaccinia virus, modified to increase its safety, tumor selectivity and anti-tumor activity. Virus-mediated oncolysis results in immunogenic cell death and triggers immune activation and memory for long-term immunotherapy against cancer. Clinical results in more than 150 subjects have shown Olvi-Vec is well tolerated with documented clinical benefits. Currently the product is in Phase III stage of development for the treatment of Platinum-Resistant/Refractory Ovarian Cancer
CAN-2409: Candel Therapeutics
CAN-2409 (aglatimagene besadenovec) is an adenovirus-based replication deficient engineered gene construct encoding the thymidine kinase gene derived from the herpes simplex virus. It is injected directly into the tumor or target tissue The prodrug-derived cytotoxic nucleotide analogs are designed to inhibit DNA replication and repair, leading to the death of multiplying tumor cells, and in particular of cells undergoing repair from radiation or chemotherapy damage. Currently the product is in Phase III stage of development for the treatment of Prostrate Cancer.
CG0070: CG Oncology
CG0070 is an investigational oncolytic immunotherapy based on a modified common cold adenovirus backbone that contains a cancer-specific promoter and a GM-CSF transgene. CG0070, first replicates inside the tumor's cells causing tumor cell lysis and immunogenic cell death. Then, the rupture of the cancer cells can release tumor-derived antigens, along with GM-CSF, that can stimulate a systemic anti-tumor immune response that involves the body's own white blood cells. CG0070 is in development for a variety of solid tumor types to be used alone or in combination with immune checkpoint modulators. The therapy is in clinical development for the treatment of Bladder cancer and preclinical studies for solid tumors. In advanced clinical studies, CG0070 has been shown to be a safe and efficacious agent in NMIBC following BCG failure. Currently the product is in Phase III stage of development for the treatment of Non Muscular Invasive Bladder Cancer.
Pelareorep: Oncolytics Biotech
Pelareorep, is an investigational drug being developed by Oncolytics Biotech. It is an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Currently the drug is being investigated in Phase III stage of Clinical trial evaluation for the treatment of Metastatic Breast Cancer.
ParvOryx: Oryx GmbH
ParvOryx is an oncolytic parvovirus H1 (H-1PV), a wild type rat virus that infects and lyses tumor cells from a wide variety of cancers. These tumor types include glioblastoma multiforme, pancreatic cancer, breast cancer, lung cancer, melanoma, lymphoma, pediatric tumors such as neuroblastoma and medulloblastoma, prostate cancer and renal cancer, as well as tumor stem cells. H-1PV acts at relatively low multiplicities of infection. The virus exerts both cytotoxic and oncolytic (replication) effects. The cytotoxic effect is predominantly mediated by the non-structural protein (NS1), resulting in cell transcription dysregulation, cell cycle arrest, cell replication shut off, and activation of cellular stress response and induction of cell death. In addition, viral oncolysis induces a strong tumor-specific immune response leading to the recognition and elimination of minimal residual disease (bystander effect). ParvOryx is the smallest of all oncolytic viruses and is able to cross the blood brain barrier. Unlike other natural or modified oncolytic viruses currently under investigation, ParvOryx does not affect normal cells and is not pathogenic to humans. Currently the product is in Phase II stage of development for the treatment of pancreatic cancer.
SND005: Jiangsu Sinorda Biomedicine
SND005 Oncolytic virus is a type of virus that preferentially infects and kills tumor cells. Initially, some tumor cells were specifically infected and destroyed by oncolytic viruses. Subsequently, the oncolytic virus replicates and proliferates in tumor cells, releasing new infectious virus particles to infect and destroy other tumor cells. Oncolytic viruses exert their oncolytic effects by directly lysing tumor cells or stimulating the host to produce an anti-tumor immune response. Among the new oncolytic virus drugs currently underway, SND005 is the only wild-type virus without genetic modification. It has a 14 - year history of clinical use. In a trial of 540 patients with melanoma, more than 44% of the patients benefited. In the safety and tolerability study of 190 patients, no serious adverse events were found, and the most common adverse event was low-grade fever. The clinical data and observations after the overseas market show that the survival rate of patients is increased by 4- 5 times, and it has excellent performance in stage II melanoma patients.
VCN-01: VCN Biosciences
VCN-01 is an innovativeconditionally replicative oncolytic adenovirus expressing PH20 hyaluronidase. Expression of hyaluronidase from VCN-01 facilitates virus penetration and decreases intratumorfluid pressure, enhancing antibodyup-take. In addition, VCN-01 capsid has been modified to allow the virus to partially evade liver tropism and target selectively the tumor after intravenous administration. Currently the product is in Phase I stage of development for the treatment of Pancreatic, Serous Epithelial Ovarian Cancer and Squamous Cell of Head and Neck.
The Oncolytic Virus Cancer Therapy Pipeline Report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Oncolytic Virus Cancer Therapy with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Oncolytic Virus Cancer Therapy Treatment.
Oncolytic Virus Cancer Therapy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Oncolytic Virus Cancer Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Oncolytic Virus Cancer Therapy market.
Learn more about Oncolytic Virus Cancer Therapy Drugs opportunities in our groundbreaking Oncolytic Virus Cancer Therapy research and development projects @ Oncolytic Virus Cancer Therapy Unmet Needs
Oncolytic Virus Cancer Therapy Companies
Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Oncolys BioPharma, Turnstone Biologics and others.
Oncolytic Virus Cancer Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intranasal
Intravenous
Oral
Oral/Intravenous
Parenteral
Subcutaneous
Subcutaneous/Intramuscular
Oncolytic Virus Cancer Therapy Products have been categorized under various Molecule types such as
Oncolytic Virus
Discover the latest advancements in Oncolytic Virus Cancer Therapy treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Oncolytic Virus Cancer Therapy Market Drivers and Barriers, and Future Perspectives
Scope of the Oncolytic Virus Cancer Therapy Pipeline Report
Coverage- Global
Oncolytic Virus Cancer Therapy Companies- Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Oncolys BioPharma, Turnstone Biologics and others.
Oncolytic Virus Cancer Therapy Pipeline Therapies- Gemcitabine, Valacyclovir, CG0070, Keytruda, atezolizumab, Ipilimumab, TBI-1401(HF10), Bevacizumab, Sorafenib, Pembrolizumab, Talimogene Laherparepvec and others.
Oncolytic Virus Cancer Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Oncolytic Virus Cancer Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Oncolytic Virus Cancer Therapy Pipeline on our website @ Oncolytic Virus Cancer Therapy Emerging Drugs and Companies
Table of Contents
Introduction
Executive Summary
Oncolytic Virus Cancer Therapy: Overview
Pipeline Therapeutics
Therapeutic Assessment
Oncolytic Virus Cancer Therapy– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Olvi-Vec: Genelux Corporation
Mid Stage Products (Phase II)
SND005: Jiangsu Sinorda Biomedicine
Early Stage Products (Phase I/II)
AloCelyvir: Orgenesis
Early Stage Products (Phase I)
VCN-01: VCN Biosciences
Preclinical and Discovery Stage Products
SynOV 1.3: Beijing Syngentech
Inactive Products
Oncolytic Virus Cancer Therapy Key Companies
Oncolytic Virus Cancer Therapy Key Products
Oncolytic Virus Cancer Therapy- Unmet Needs
Oncolytic Virus Cancer Therapy- Market Drivers and Barriers
Oncolytic Virus Cancer Therapy- Future Perspectives and Conclusion
Oncolytic Virus Cancer Therapy Analyst Views
Oncolytic Virus Cancer Therapy Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
16 minutes ago
- National Post
Mobileum Earns Industry Recognition from Juniper Research for Its Voice Fraud Prevention and Trust Solutions
Article content Mobileum's Risk Management and Security portfolio provides real-time, AI-powered protection and innovative branded calling solutions to help telecom operators combat robocalling and enhance customer trust Article content CUPERTINO, Calif. — Mobileum Inc. ('Mobileum'), a leading global provider of analytics and network solutions, is proud to announce its recognition as one of the top vendors in Juniper Research's latest report, Robocall Mitigation & Branded Calling Market: 2025–2030. The study reflects Mobileum's continued leadership in helping communications service providers (CSPs) combat fraud, safeguard the voice channel, and restore consumer trust through advanced risk mitigation and branded calling solutions. Article content With robocall-related fraud forecast to peak at over $80 billion in 2025, the voice channel faces growing pressure. At the same time, the adoption of branded calling, where verified caller IDs help rebuild consumer trust, is accelerating rapidly. According to Juniper, branded-calling authentication API calls are projected to grow by more than tenfold between 2024 and 2029, indicating a significant shift in the industry toward identity-based frameworks and authenticated communications. Global revenue from branded calling is projected to reach $2.3 billion by 2030, driven by strong commercial demand for more secure and trusted voice communications. Mobileum's AI-powered solutions and branded calling capabilities play an essential role in enabling this transformation, helping CSPs detect and mitigate fraud, authenticate voice traffic, and deliver secure voice experiences at scale. Article content Mobileum's award-winning solutions, built on its modular Active Intelligence Platform (AIP), deliver powerful, real-time protection against Calling Line Identity (CLI) spoofing, robocalls, and other forms of telecom voice fraud. These include: Article content Voice Firewall – leverages AI-driven traffic analysis and adaptive policy enforcement to detect, flag, and block unwanted calls, providing granular protection against CLI spoofing and voice fraud (such as robocalls, vishing, Wangiri, revenue share, bypass, flash calls, unauthorized access, denial-of-service, etc.) RAID 9 Platform / RAID FMS – relies on AI and machine learning to analyze network data, including Signaling, Call Detail Records (CDRs), Test Call Generator (TCG) output, and user profile analysis to detect fraudulent behavior, reduce manual oversight, and enable rapid, automated responses. Signaling Firewalls – defend against malicious attacks across SS7, Diameter, GTP and 5G protocols, strengthening core network security. SMS Firewall – leverages AI/ML to analyze and protect the SMS service across multiple protocols (i.e., SIP, SMPP, GSM-MAP). Additionally, it includes Mobileum's leading URL scanner solution, which ensures that potentially unsafe hyperlinks are analyzed and the appropriate action is taken to protect the end customer. Article content Together, these solutions empower CSPs to maintain trust, ensure compliance, and operate with greater security and efficiency in a rapidly evolving threat landscape. Article content As the voice channel evolves, Mobileum enables operators to deliver branded, secure communications that not only reduce fraud but also deliver measurable business value – lowering support costs, preventing revenue leakage, and offering premium, branded calling features that deepen enterprise engagement. Article content 'Our recognition by Juniper Research reaffirms the effectiveness of our fraud mitigation and branded calling solutions in today's increasingly complex telecom environment,' said Avnish Chauhan, Chief Technology Officer at Mobileum. 'We're proud to help our customers stay ahead of sophisticated and evolving threats while delivering intelligent, secure communications at scale.' Article content This recognition further consolidates Mobileum's position as a trusted partner for telecom operators navigating the dual imperative of fraud prevention and enhanced customer engagement. As branded calling adoption accelerates and AI-powered scams become more sophisticated, Mobileum remains committed to innovation that protects and modernizes the global telecom ecosystem. Article content About Mobileum Inc. Article content Mobileum is a leading provider of Telecom analytics solutions for roaming, core network, security, risk management, domestic and international connectivity testing, and customer intelligence. More than 1,000 customers rely on its Active Intelligence platform, which provides advanced analytics solutions, allowing customers to connect deep network and operational intelligence with real-time actions that increase revenue, improve customer experience, and reduce costs. Headquartered in Silicon Valley, Mobileum has global offices in Australia, Germany, Greece, India, Japan, Portugal, Singapore, UK, and United Arab Emirates. Article content Article content Article content Article content Article content Contacts Article content Useful Contacts: Article content QUEXOR GROUP INC. Article content Article content Cheryl Fritz | Article content cfritz@ Article content | Mob.: +1 (703) 856-5932 Article content Media and Corporate Communications Article content – Mobileum Article content Article content Article content
National Post
16 minutes ago
- National Post
Swissbit to Debut at Black Hat USA 2025
Article content WESTFORD, Mass. — Swissbit, a leading manufacturer of storage and security solutions, will make its debut at Black Hat USA on August 6–7, 2025, at the Mandalay Bay Convention Center in Las Vegas. At booth #6025, Swissbit will showcase its unique approach to cybersecurity – protecting the often-neglected physical layer of connected systems, from IoT and industrial equipment to critical infrastructure and edge devices. All Swissbit products, including its latest security innovations, are manufactured in Germany to ensure a transparent supply chain, industrial-grade quality, and trusted reliability. Exposing the hidden risk: physical access to embedded systems While much focus is placed on cloud and AI infrastructure, a critical security gap remains: Physical attacks on embedded and edge systems. Often deployed in remote or exposed environments, these systems are vulnerable to tampering and data theft. From smart meters and PLCs to drones, the consequences can be serious. Swissbit addresses this threat with plug-and-play, hardware-based solutions that secure both new and legacy systems, without the need for major redesigns. Article content Article content 'We're excited to bring Swissbit's expertise to Black Hat for the first time,' said Claus Gründel, General Manager Security Solutions at Swissbit. 'Physical attacks are a growing risk that many still underestimate. We provide easy-to-integrate, hardware-based security that protects systems and data at the edge, where software alone isn't enough.' Hardware-based protection for data and devices Article content At Black Hat, Swissbit will demonstrate secure storage products such as microSD cards with AES-256 encryption and secure boot capabilities. These solutions retrofit embedded systems and protect edge-generated data like video and sensor streams from unauthorized access. By enabling compliance with regulations such as the EU Cyber Resilience Act and NIS2, Swissbit offers a future-proof path to stronger, more sustainable cybersecurity. Article content Bridging digital and physical access with iShield Key 2 Article content Also featured at the Swissbit booth: the new iShield Key 2 series -compact security keys that combine FIDO-based multi-protocol authentication with physical access control. Tailored for enterprise and government use, they integrate secure login and facility entry into a single, robust solution for digital identity and access protection. Article content Article content Article content Article content
National Post
16 minutes ago
- National Post
Zoho Launches Zia LLM and Deepens AI Portfolio with Prebuilt Agents, Custom Agent Builder, MCP, and Marketplace
Article content Homegrown, Business-Optimized Technology Addresses Needs for Developers and End Users While Enhancing Platform Capabilities Article content AUSTIN, Texas — Zoho Corporation, a global technology company, today announced additional investments and offerings in AI, including Zia LLM, a proprietary large language model; Zia Agents, with 25+ ready-to-deploy AI-powered agents available in Agent Marketplace; Zia Agent Studio, a no-code agent builder; and a model context protocol (MCP) server to open up Zoho's vast library of actions to third-party agents. These capabilities and investments are designed to help organizations fully realize and maximize the value of contextual, assistive and agentic AI technology. Immediately impacting daily workflows for diverse roles and use cases, Zoho's latest AI developments deliver operational and financial efficiencies across entire organizations. Article content 'Today's announcement emphasizes Zoho's longstanding aim to build foundational technology focused on protection of customer data, breadth and depth of capabilities, and value,' said Mani Vembu, CEO at Zoho. 'Because Zoho's AI initiatives are developed internally, we are able to provide customers with cutting-edge tool sets without compromising data privacy and organizational flexibility, democratizing the latest technology on a global scale.' Zia LLM, Built from the Ground Up and Optimized for Business Article content Zoho has successfully launched its own large language model, Zia LLM, built completely in-house by leveraging NVIDIA's AI accelerated computing platform. Trained with Zoho product use cases in mind—ranging from structured data extraction, summarization, RAG, and code generation—Zia LLM is comprised of three models with 1.3 billion, 2.6 billion and 7 billion parameters, each separately trained and optimized for contextual applicability that benchmark competitively against comparable open source models in the market. The three models allow Zoho to always optimize the right model for the right user context, striking the proper balance between power and resource management. This focus on right-sizing the model is an ongoing development strategy for Zoho. Article content In addition to Zia LLM, Zoho is announcing two proprietary Automatic Speech Recognition (ASR) models for speech-to-text conversion for both English and Hindi. Optimized to perform on a low computer load without compromising on accuracy, the models benchmark up to 75% better than comparable models across standard tests. Language support for additional languages will be coming in the future. Article content While Zoho supports many LLM integrations for users, including ChatGPT, Llama, and DeepSeek, Zia LLM continues Zoho's commitment to data privacy by allowing customers to keep their data on Zoho servers, leveraging the latest AI capabilities without sending their data to AI cloud providers. Article content Zia LLM will be deployed across Zoho's data centers in the US, India, and Europe. The model is currently testing for internal use cases across Zoho's broad app portfolio, and will be available for customer use in coming months. Article content Effective Native AI Agents Ready for Use Article content To enable immediate adoption of agentic technology, Zoho has developed a roster of AI agents contextually baked right into its products. These agents can be used across various business activities, handling relevant actions based on real-life organizational roles (including sales development, customer support, and account management). Article content Agents available today include: Article content New Version of Ask Zia: The latest version of Zoho's platform-wide conversational AI assistant, Ask Zia 's new BI skills are tailored to data engineers, analysts, and data scientists, yet supports any user within an organization. Ask Zia is now equipped with capabilities that directly address the unique pain points faced by each persona, whether it's building end-to-end data pipelines for engineers, analyzing data, creating reports and dashboards in an interactive conversation mode for analysts, or helping to jump start building ML models for data scientists. Customer Service Agent: With the ability to process incoming customer requests, understand the context behind them, and either answer them directly or triage them to a human rep, the Customer Service Agent for Zoho Desk provides an efficient yet reliable first line of assistance, paving the way for quicker responses and resolutions. Article content AI Agent Studio and Marketplace Article content First announced Article content earlier in 2025, Zoho has further simplified the Article content Zia Agent Studio Article content experience to be fully prompt-based (with the option to use low-code) and include ready-made access to over 700 actions across Zoho's products. Agents built by users can be deployed autonomously, triggered through button click or rule-based automation, or summoned within customer conversations. Article content At the time of deployment, an agent can also be provisioned as a digital employee. Digital Employees respect defined user access permissions, maintaining the same permissions structures already defined within the organization. Admins are able to perform behavioral audits as well as performance and impact analyses on Digital Employees, ensuring that every agent is working as effectively as possible and within clear guardrails. Article content Zoho Marketplace, Article content which supplies over 2500 reliable extensions and integrations for Zoho users, now houses the Article content Agent Marketplace Article content , a dedicated section for AI agents that can be deployed by customers quickly. Ecosystem partners, ISVs, and individual developers will soon be able to create agents and host them on the Zia Agents Marketplace, further simplifying the adoption of agentic technology by organizations. Article content Some pre-built agents created with Zia Agent Studio (and available on the Zia Agent Marketplace) are: Article content Revenue Growth Specialist: Uncovers opportunities for upsell and cross-sell across existing customers, recommending the best marketing approach for each customer. Deal Analyzer: Analyze deals and provide insights such as win probability, next best action, and follow-up suggestions. Candidate Screener: Intelligently identifies and ranks the most suitable candidates for a specific job opening based on role requirements, skills, experience, and other key attributes. Article content Zoho will continue to add more pre-built agents to the Agent Marketplace over time to cover several valuable core and utility use cases across various business functions. The full list of available agents can be found under Additional Documentation. Article content With over 55 applications across one ecosystem, users can build agents to meet their organization's every need, no matter how specific. With Zia Agent Studio, Zoho users have access to the same tools as Zoho's developers, ensuring that any agent a customer dreams of can be created with ease. Article content Interoperability with MCP Article content Zoho has adopted the model context protocol (MCP), offering its own MCP server with a rich action library across several applications, allowing any MCP client to tap into data and actions from various Zoho apps while respecting the customer's defined permission structures. Article content Zoho's MCP server has a library of actions from more than 15 Zoho applications exposed during Early Access. With Zoho Flow, third party tools are also exposed. Additional Zoho applications will be onboarded in the coming months. Furthermore, Zoho Analytics now offers support for a local MCP server. Article content Roadmap Article content In the short term, Zoho will regularly scale Zia LLM's model sizes, starting with the first of several planned parameter increases by the end of 2025. Future planned releases include expanding the available languages used by the speech-to-text model, beginning with languages spoken primarily across Europe and India, as well as the introduction of a reasoning language model (RLM). Article content Additional skills will be added to Ask Zia, allowing it to act as an assistant to Finance teams and Customer Support teams, with more skills added in the future. Article content Support for the Agent2Agent (A2A) protocol will be implemented, allowing for Zia Agents to interact and collaborate with each other, as well as collaborate with agents on other platforms. Article content Additional Documentation Article content Disclaimer Article content All trademarks, product names, and company names cited herein are the property of their respective owners. Article content Availability and Pricing Article content Zia LLM will be available to Zoho customers in the coming months. Zia Agents, Zia Agent Studio, Agent Marketplace, and Zoho MCP Server are being rolled out to customers who are currently on the early access waiting list. General availability for these offerings is expected towards the end of 2025. Zoho expects to study the usage patterns of these customers across use cases, industries, geographical regions, and sizes during this early access phase. A pricing structure for these offerings can be expected at the time of general availability. Article content Zoho Artificial Intelligence Differentiation Article content Zoho is committed to designing and incorporating artificial intelligence guided by the principles of customer privacy and value. Our generic AI models across contextual, assistive, and agentic AI, are not trained on consumer data and do not retain customer information. Zoho builds AI tools with usefulness in mind, striking a balance between providing AI technology that assists workers while right-sizing models that don't require burdening consumers with additional costs. Article content Zoho Privacy Pledge Article content Article content Article content Article content Contacts Article content Media Contacts: Article content
